{
  "asset": {
    "name": "SKYTROFA (TransCon hGH)",
    "company": "Ascendis Pharma A/S",
    "ticker": "ASND",
    "target": "Human growth hormone",
    "mechanism": "Once-weekly TransCon prodrug releasing hGH",
    "modality": "TransCon prodrug",
    "partner": null
  },
  "clinical_development": {
    "current_stage": "Approved",
    "indications_in_development": [
      "Pediatric and adult growth hormone deficiency",
      "Turner syndrome",
      "Small for gestational age",
      "Idiopathic short stature",
      "SHOX deficiency",
      "Achondroplasia",
      "Hypochondroplasia"
    ]
  },
  "trials": [],
  "investment_thesis": [],
  "key_risks": [],
  "upcoming_catalysts": [],
  "_source_pages": [
    3,
    13,
    14
  ],
  "_last_extracted": "2026-02-04T13:33:12.100493"
}